CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy

PartnershipHMPL-A830Positive
AI Analysis

Summary

GSK acquired exclusive global rights to HUTCHMED's HMPL-A830, a combination EGFR antibody and KRAS inhibitor for solid tumors, for $110 million upfront with potential total payments of $1.3 billion.

Importance:7/10
Sentiment:
0.70
licensingpartnershiponcologyAsia allianceEGFR inhibitorKRAS inhibitor
Related Companies

Read the original article

Published by BioSpace on September 3, 2026 12:46 PM

Read Original